Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8166563 | 1.00 | CCNE1 (0.32) | CCNE1CDK2GSK3BMEN1KMT2A | |
| SCHEMBL12757777 | 1.00 | CCNE1 (0.32) | CCNE1CDK2GSK3BMEN1KMT2A | |
| SCHEMBL12621033 | 0.81 | CCNE1 (0.32) | CCNE1CDK2GSK3BMEN1KMT2A | |
| SCHEMBL1803056 | 0.81 | CCNE1 (0.32) | CCNE1CDK2GSK3BMEN1KMT2A | |
| SCHEMBL16575072 | 0.81 | CCNE1 (0.36) | CCNE1CDK2GSK3BMEN1KMT2A | |
| SCHEMBL8129220 | 0.81 | CCNE1 (0.36) | CCNE1CDK2GSK3BMEN1KMT2A | |
| SCHEMBL7875278 | 0.81 | CCNE1 (0.36) | CCNE1CDK2GSK3BMEN1KMT2A | |
| SCHEMBL1128725 | 0.81 | CCNE1 (0.36) | CCNE1CDK2GSK3BMEN1KMT2A | |
| SCHEMBL2624001 | 0.81 | CCNE1 (0.36) | CCNE1CDK2GSK3BMEN1KMT2A | |
| SCHEMBL12757780 | 0.80 | CCNE1 (0.33) | CCNE1CDK2GSK3BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9808527-B2 | Methods and compositions for treating HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2017-11-07 | — | — | US | disclosed |
| US-9808527-B2 | Methods and compositions for treating HIV infections | PURDUE RESEARCH FOUNDATION (US) | 2017-11-07 | — | — | US | disclosed |
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113582-A1 | METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS | SERPINB1, HPN, PRSS1 | CCNE1 1568/4885CDK2 527/4885GSK3B 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.